Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMC - Industry leading Diabetes Drug -- Ignore unavailable to you. Want to Upgrade?

To: David in Ontario who wrote (17)	3/22/1999 11:56:00 AM
From: Rich Kaiser	Respond to of 55

Hi Dave, Always good to see you on a thread. Management appears very confident about the near term performance for the Company. The single biggest reason why the stock came off from its Dec. high was the financial problems in Brazil. Remember: Immunis get 25% of all sales of the DAIB-II drug anywhere outside of China. Currently, the Company will show the efforts of Biotech arrangements in S. America. To say the least, investors who got spooked because they didn't understand simple Health Economics(meaning there is no direct correlation between someone who is sick and that of the macroeconomic situation as a whole left good value stock on the table for the value seeking investors. So, if you are sick and the economy around you continue to shrink you are still going to get medical attention. Rich

To: David in Ontario who wrote (17)	3/30/1999 12:32:00 PM
From: Rich Kaiser	Read Replies (4) \| Respond to of 55

Hi Dave, It looks really good for IMMC for two reason: 1) The financial world has been putting out a lot of information, in a number of publication ,about the Drug industries low price stock in terms of their performances. 2)IMMC should be coming out with news because today BIotech had a release about signing a deal with a major player in Argentina. IMMC will receive 25% of the revenue generated from this agreement. This agreement and the pending agreement in Brazil will ensure that IMMC meet it earning expectation for 1999 around $0.25 I'm very excited about the whole situation... At these levels and with NO debt and small public float. IMMC should be a serious consideration. With best Regards Rich